研究者業績

長谷川 眞也

ハセガワ マサヤ  (Masaya Hasegawa)

基本情報

所属
藤田医科大学 医療科学部・研究推進ユニット・レギュラトリーサイエンス分野 助教

連絡先
masaya.hasegawafujita-hu.ac.jp
研究者番号
01019141
ORCID ID
 https://orcid.org/0009-0002-5125-314X
J-GLOBAL ID
202501009057676850
researchmap会員ID
R000088604

外部リンク

論文

 14
  • Koyo Yoshidomi, Kazuo Kunisawa, Masaya Hasegawa, Yuki Kon, Aika Kosuge, Moeka Tanabe, Haruto Ojika, Yasuko Yamamoto, Hidetsugu Fujigaki, Suwako Fujigaki, Hiroyuki Tezuka, Sei Saitoh, Kanako Kumamoto, Masanori Kugita, Shizuko Nagao, Kuniaki Saito, Toshitaka Nabeshima, Akihiro Mouri
    Neurochemistry international 195 106141-106141 2026年3月5日  査読有り
    Multiple sclerosis (MS) is a common autoimmune demyelinating disease of the central nervous system (CNS). Although activation of the kynurenine (KYN) pathway has been observed in patients with MS, its pathological significance remains unclear. In this study, we investigated the role of the KYN pathway in MS using an experimental autoimmune encephalomyelitis (EAE) mouse model, a widely recognized animal model of MS. We found an increase in the expression of kynureninase (KYNU), a key enzyme in the KYN pathway that is specifically localized within monocytes in the spinal cord of EAE mice. This was accompanied by a significant accumulation of quinolinic acid (QUIN) in the spinal cord. Importantly, similar increases in KYNU expression and QUIN levels were observed in the spinal cord of proteolipid protein overexpressing mice (PLP-tg mice), another model of demyelination. Notably, KYNU knockout (KO) reduced EAE severity and monocyte recruitment to the spinal cord of EAE model mice. These findings suggest that the increase in KYNU expression and the subsequent accumulation of QUIN may contribute to the exacerbation of MS. Taken together, our results indicate that KYNU could be a novel therapeutic target for MS.
  • Takatoshi Sakata, Kazuo Kunisawa, Masaya Hasegawa, Yumiko Seto, Aoi Ogawa, Hitomi Kurahashi, Yasuko Yamamoto, Masao Takemura, Hidetoshi Matunami, Tomoya Sugai, Noriki Kutsumura, Kuniaki Saito, Toshitaka Nabeshima, Akihiro Mouri
    British Journal of Pharmacology 2025年12月21日  査読有り
  • Haruki Fujisawa, Nobuhiko Magara, Shogo Nakayama, Sachiho Fuse, Naoko Iwata, Masaya Hasegawa, Hisayoshi Kubota, Hirotaka Shoji, Satoko Hattori, Hideo Hagihara, Hidetsugu Fujigaki, Yusuke Seino, Akihiro Mouri, Tsuyoshi Miyakawa, Toshitaka Nabeshima, Atsushi Suzuki, Yoshihisa Sugimura
    Molecular neurobiology 62(9) 12078-12093 2025年9月  査読有り
    Hyponatremia is the most common clinical electrolyte disorder. Once thought to be asymptomatic in response to adaptation by the brain, recent evidence suggests that chronic hyponatremia (CHN) may induce neurological manifestations, including psychological symptoms. However, the specific psychological symptoms induced by CHN, the mechanisms underlying these symptoms, and their potential reversibility remain unclear. Therefore, this study aimed to determine whether monoaminergic neurotransmission is associated with innate anxiety-like behaviors potentiated by CHN in a mouse model of CHN secondary to the syndrome of inappropriate antidiuresis. In the present study, using a mouse model of the syndrome of inappropriate antidiuresis presenting with CHN, we showed that the sustained reduction of serum sodium ion concentrations potentiated innate anxiety-like behaviors in the light/dark transition and open field tests. We also found that serotonin and dopamine levels in the amygdala were significantly lower in mice with CHN than in controls. Additionally, phosphorylation of extracellular signal-regulated kinase (ERK) in the amygdala was significantly reduced in mice with CHN. Notably, after correcting for CHN, the increased innate anxiety-like behaviors, decreased serotonin and dopamine levels, and reduced phosphorylation of ERK in the amygdala were normalized. These findings further underscore the importance of treating CHN and highlight potential therapeutic strategies for alleviating anxiety in patients with CHN, which will improve their quality of life.
  • Moeka Tanabe, Kazuo Kunisawa, Imari Saito, Aika Kosuge, Hiroyuki Tezuka, Tomoki Kawai, Yuki Kon, Koyo Yoshidomi, Akari Kagami, Masaya Hasegawa, Hisayoshi Kubota, Haruto Ojika, Tadashi Fujii, Takumi Tochio, Yoshiki Hirooka, Kuniaki Saito, Toshitaka Nabeshima, Akihiro Mouri
    Molecular psychiatry 30(5) 2137-2151 2025年5月  査読有り
    Negative experiences during adolescence, such as social isolation (SI), bullying, and abuse, increase the risk of psychiatric diseases in adulthood. However, the pathogenesis of psychiatric diseases induced by these factors remain poorly understood. In adolescents, stress affects the intestinal homeostasis in the gut-brain axis. This study determined whether adolescent SI induces behavioral abnormalities by disrupting colonic function. Adolescent mice exposed to SI exhibit spatial cognitive deficits and microglial activation in the hippocampus (HIP). SI decreased the differentiation of mucin-producing goblet cells, which was accompanied by alterations in the composition of the gut microbiota, particularly the depletion of mucin-feeding bacteria. Treatment with rebamipide, which promotes goblet cell differentiation in the colon, attenuated SI-induced spatial cognitive deficits and microglial activation in the HIP and decreased cystine, a downstream metabolite of homocysteine. Treatment with cystine ameliorated SI-induced spatial cognitive deficits and increased microglial C-C motif chemokine ligand 7 (CCL7) levels in the HIP. Inhibition of CCL7 receptors by antagonists of CC motif chemokine receptors 2 (CCR2) and 3 (CCR3) in the HIP prevented spatial cognitive deficits induced by SI. Infusion of CCL7 into the HIP following microglial ablation with clodronate liposome induced spatial cognitive deficits. These findings suggest that adolescent SI decreases serum cystine levels by damaging the colonic goblet cells, resulting in spatial cognitive deficits by triggering microglial activation in the HIP. Our results indicate that increased CCL7 expression in hippocampal microglia may contribute to spatial cognitive deficits by activating CCR2 and CCR3.
  • Hitomi Kurahashi, Kazuo Kunisawa, Kenji F Tanaka, Hisayoshi Kubota, Masaya Hasegawa, Mai Miyachi, Yuka Moriya, Yoichi Hasegawa, Taku Nagai, Kuniaki Saito, Toshitaka Nabeshima, Akihiro Mouri
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 50(5) 739-750 2025年4月  査読有り
    Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behaviors, social deficits, and cognitive impairments. Maternal use of valproic acid (VPA) during pregnancy is associated with an increased risk of ASD in offspring. The prevailing pathophysiological hypothesis for ASD involves excitation/inhibition (E/I) imbalances and serotonergic dysfunction. Here, we investigated the association between glutamatergic-serotonergic neuronal interactions and ASD-like behaviors in mice exposed to prenatal VPA. Prenatal VPA exposure induced excessive repetitive self-grooming behavior and impaired social behavior and object recognition memory in young adult period. Prenatal VPA mice showed hyper-glutamatergic function (increase in basal extracellular glutamate levels and CaMKII phosphorylation) and hypo-serotonergic function (decrease in 5-hydroxyindoleacetic acid and stimulation-induced serotonin [5-HT] release, but an increase in 5-HT transporter expression) in the prefrontal cortex. Treatment with a low-affinity NMDA receptor antagonist (memantine), a selective 5-HT reuptake inhibitor (fluoxetine), and a 5-HT1A receptor agonist (tandospirone) attenuated both the increase in CaMKII phosphorylation and ASD-like behavior of prenatal VPA mice. Opto-genetic activation of the serotonergic neuronal system attenuated impairments in social behavior and object recognition memory in prenatal VPA mice. WAY-100635-a 5-HT1A receptor antagonist-antagonized the effect of fluoxetine on impaired social behavior and object recognition memory. These results suggest that E/I imbalance and ASD-like behavior are associated with hypo-serotonergic receptor signaling through 5-HT1A receptors in prenatal VPA mice.

MISC

 2
  • 森田優希, 毛利彰宏, 國澤和生, 大原健太郎, 山崎晃, 西川貴也, 石坂友紀乃, 長谷川眞也, 倉橋仁美, 田辺萌夏, 坂田昂駿, 三宅優菜, 藤垣英嗣, 齋藤邦明, 鍋島俊隆
    日本薬理学雑誌 160(Supplement) 2025年  
  • 毛利 彰宏, 長谷川 眞也, 國澤 和生, 齋藤 邦明, 鍋島 俊隆
    日本薬理学雑誌 158(3) 233-237 2023年5月1日  
    うつ病の病態にはモノアミン仮説が提唱されており,抗うつ薬の主流が選択的セロトニン(5-HT)再取り込み阻害薬であることから,特に5-HT神経系の機能低下が広く受け入れられている.しかし,患者の約1/3は既存の抗うつ薬に対して難治性であるため,新しい創薬ターゲットに対する新規抗うつ薬の開発が求められている.トリプトファン(TRP)は5-HT経路だけでなくキヌレニン(KYN)経路においても代謝される.インドールアミン2,3-ジオキシゲナーゼ1(IDO1)は,TRP-KYN経路の代謝を行う最初の律速酵素である.IDO1は炎症性サイトカインによって強く誘導され,TRPを代謝し,5-HT経路で代謝されるTRPレベルを低下させ,その結果,5-HT合成を抑制し,うつ様行動を惹起する.下流のキヌレニン-3-モノオキシゲナーゼ(KMO)は,KYNを3-ヒドロキシキヌレニンに代謝する重要な酵素である.KMOが欠損すると,キヌレニンアミノトランスフェラーゼ(KAT)によりKYNが代謝され,キヌレン酸(KA)が増加し,うつ様行動が惹起される.一方,慢性予測不能軽度ストレス(CUMS)は視床下部-下垂体-副腎皮質(HPA)系を破綻させ,前頭前野におけるKMOの発現が低下し,KAを増加させる.これにはCUMSによるKMOを主に発現するミクログリアの減少を伴っている.KAはα7ニコチン性アセチルコリン受容体(α7nAChR)アンタゴニスト作用を有する.ニコチンやガランタミンによるα7nAChRの活性化により,CUMS誘発のうつ病様行動が減弱される.IDO1の誘導による5-HT合成抑制と,KMO発現低下を介したKAレベルの増加によるα7nAChR拮抗作用はうつ様行動を引き起こすことから,TRP-KYN経路の代謝的変化がうつ病の病態に深く関与していると考えられる.TRP-KYN経路は,うつ病の新規診断方法や抗うつ薬の開発に向けた魅力的なターゲットになることが期待される.

担当経験のある科目(授業)

 4

所属学協会

 3

共同研究・競争的資金等の研究課題

 3